NEW YORK, NY / ACCESSWIRE / December 21, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, announces that it is investigating potential violations of the federal securities laws by Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata" or the "Company").
On December 6, 2021, the U.S. Food and Drug Administration ("FDA") released a briefing document regarding the Company's chronic kidney disease drug candidate, bardoxolone methyl, which revealed Reata did not "demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome]." On this news, the Company's stock price fell 40%.
If you currently own stock or options in RETA and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476, via email at [email protected], or by filling out this form.
About the Firm
Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at labaton.com.
CONTACT:
David J. Schwartz
(800) 321-0476
[email protected]
SOURCE: Labaton Sucharow LLP